About

About AMS AMS is a venture-backed Nuclear Medicine start-up leading the transformation of Japan’s nuclear sector. In the wake of the 2011 Fukushima nuclear accident, AMS is pioneering a new generation of nuclear medicine technologies that address systemic inefficiencies, regulatory bottlenecks, and limited access within the domestic market — through a dual focus on clinical innovation and infrastructure advancement. With two integrated business divisions — Theranostics Development (TD) and Engineering Solutions (ES) — AMS is positioned to shape the future of precision healthcare across the country. In its TD business, AMS is introducing next-generation PET diagnostics, including 68Ga-PSMA, and supporting the development of novel radiotherapeutics such as astatine-211 (211At) to meet growing demand for targeted oncology solutions. These efforts are grounded in AMS’s proprietary expertise in medical device development, radiochemistry, and regulatory strategy. The resulting innovations are aligned with global trends and address pressing needs in a domestic market seeking scalable, high-impact care modalities. Complementing this, AMS’s ES business tackles a critical barrier in the delivery of nuclear medicine: the safe and efficient management of radioactive discharge. The company has developed a proprietary bedside filtration system that streamlines regulatory compliance, reduces operational burden, and significantly improves patient throughput by enabling faster discharge and more rapid room turnover. This empowers hospitals to treat more patients within existing infrastructure, drives revenue growth, and facilitates earlier discharge for patients. Additionally, the platform generates actionable clinical data to support treatment decision-making and ensure the safe handling of radioactive materials. With a differentiated portfolio, strong regulatory alignment, and robust investor backing, AMS presents a compelling opportunity in Japan’s revitalized nuclear medicine sector — where cutting-edge innovation converges with urgent healthcare needs and long-term market growth.